Context Therapeutics (CNTX) Non-Current Debt (2020)
Context Therapeutics (CNTX) posted Non-Current Debt of $69040.0 for Q4 2020.
Context Therapeutics (CNTX) Non-Current Debt (2020) Analysis & Trends
Context Therapeutics has reported Non-Current Debt for 1 years, with the latest figure at $69040.0 in Q4 2020.
- Quarterly Non-Current Debt changed N/A year-over-year to $69040.0 in Q4 2020, while the trailing twelve-month figure through Dec 2020 was $69040.0 (changed N/A YoY) and the FY2020 annual result came in at $69040.0, changed N/A from the prior year.
- Non-Current Debt held at $69040.0 in Q4 2020 per CNTX's latest filing.
- Over five years, Non-Current Debt peaked at $69040.0 in Q4 2020 and troughed at $69040.0 in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.66 Bn | 131.81 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 86.52 Bn | 78.52 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 65.30 Bn | 60.11 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.18 Bn | 54.04 Bn | 52.00 Mn | 591.00 Mn |
| 5 | BeOne Medicines | 42.08 Bn | 36.98 Bn | 1.53 Bn | 882.16 Mn |
| 6 | Alnylam Pharmaceuticals | 31.77 Bn | 28.46 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.13 Bn | 9.74 Bn | 668.28 Mn | 360.97 Mn |
| 8 | Insmed | 27.51 Bn | 26.35 Bn | 358.27 Mn | 546.77 Mn |
| 9 | Royalty Pharma | 27.16 Bn | 26.32 Bn | - | 8.96 Bn |
| 10 | Context Therapeutics | 49.96 Mn | 49.96 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | 69,040.00 |